This article explains what each treatment involves, how they are sometimes used together, the current evidence base, and the important safety and regulatory considerations every patient should understand before seeking either therapy
Avoid: All GLP-1 patches until Phase 3 clinical trials demonstrate their efficacy, which is not expected until 2030 or later, when microneedle technology may enable effective transdermal delivery of medications like semaglutide
It is particularly valued in the dietary supplement and sports nutrition markets for its excellent absorption and bioavailability
The products are for research and development purposes only
There have also been cases of patients with hypokalemia while undergoing PPI treatment, with increased urinary output of potassium
Diabetes, Obesity & Metabolism, 24(8), 15531564